Versant Capital Management’s OrthoPediatrics KIDS Stock Holding History

Versant Capital Management’s Portfolio KIDS Stock Details KIDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.3K	Sell	591 -582	-50%	-$10.1K	﹤0.01%	2192
2026 Q1	$18.6K	Buy	+1,173	New	+$20.5K	﹤0.01%	1852
2025 Q4	–	Sell	-9	Closed	-$167	–	2693
2025 Q3	$167	Buy	+9	New	+$185	﹤0.01%	2612
2025 Q2	–	Sell	-214	Closed	-$5.27K	–	2684
2025 Q1	$5.27K	Buy	+214	New	+$5.29K	﹤0.01%	2013
2024 Q1	–	Sell	-12	Closed	-$390	–	1918
2023 Q4	$390	Buy	+12	New	+$348	﹤0.01%	1735

Other funds holding KIDS

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Versant Capital Management's KIDS Position: Q2 2026 in Review

Versant Capital Management reduced its OrthoPediatrics (KIDS) stake by 50% in Q2 2026, selling an estimated $10.1K and leaving 591 shares worth $11.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2192.

Versant Capital Management first reported a position in KIDS in Q4 2023 and has held it in 5 quarters since. The position peaked at $18.6K in Q1 2026. 5 funds tracked by Wall St. Rank hold KIDS as of Q2 2026.

Versant Capital Management held 591 shares of OrthoPediatrics worth $11.3K as of Q2 2026.
Versant Capital Management sold 582 OrthoPediatrics shares in Q2 2026, an estimated $10.1K.
OrthoPediatrics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2192 holding.
Versant Capital Management first reported a position in OrthoPediatrics in Q4 2023 and has held it in 5 quarters since.
Versant Capital Management's OrthoPediatrics position peaked at $18.6K in Q1 2026.
5 funds tracked by Wall St. Rank held OrthoPediatrics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.